[ad_1]
On 6th September 2022, the Azerbaijan Thalassemia Heart and BGI held a digital signing ceremony to seal a Collaboration Settlement. The partnership goals to enhance thalassemia screening in Azerbaijan by means of genetic know-how.
In early 2021, in event of the “Prevention and Management of International Haemoglobinopathies” announcement, BGI Poverty Prevention and Management Panel clearly acknowledged they search to export China’s superior applied sciences for thalassemia to ‘Belt and Street Initiative’ international locations, to collectively obtain complete thalassemia management within the world group.
In April 2022, BGI’s wholly-owned subsidiary, Huada Biotechnology (Wuhan) Co., Ltd, obtained the medical gadget registration certificates from the Nationwide Drug Administration for its alpha and beta thalassemia gene detection equipment (combining probe anchored polymerization sequencing methodology).
This settlement was signed by Dr. Valeh Hüseynov, the Government Director of Nationwide Hematology and Transfusiology Heart, Dr. Agha Rza Aghayev, the supervisor of Azerbaijan’s medical genetics division, and Mr. Jeremy Cao, the Vice President of BGI IntDx. The 2 organizations have entered a strategic partnership and can work collectively for a thalassemia research analysis venture within the nation.
Dr Agha Rza Aghayev, Azerbaijan’s medical genetics division supervisor, had the next to say: “Thanks BGI for help and collaboration, I hope this analysis program will assist us to construct an efficient and well-designed methodology for screening Thalassemia.”
Azerbaijan is without doubt one of the international locations with the very best prevalence price of thalassemia. Our thalassemia gene detection testing combines cutting-edge excessive throughput sequencing platform and benefits of low price and complete detection. It helps scientific analysis partnership in methodology comparability, enhances new know-how collaboration within the medical testing and discover the screening of thalassemia in Azerbaijan. BGI additionally has a world hemoglobinopathy basis specializing in preventing thalassemia worldwide, our aim is making the world a greater place with out this illness. BGI subsequently proposes this settlement to reaffirm that we stand along with Azerbaijan’s thalassemia middle and its folks.”
Zhiyu Peng, BGI Genomics vp
Mr Jeremy Cao, the Vice President of BGI IntDx, stated on the signing ceremony, “That is certainly one of our pioneer abroad thalassemia tasks and such settlement commits us to work collectively extra intently in the direction of widespread targets, the pursuit of screening and management of thalassemia, and the imaginative and prescient that in a not too distant future there shall be a world with out this illness. I wish to say I’m assured that by means of our efforts and dedication, we will obtain extra and to proceed to develop even stronger relationships and friendships between the folks of Azerbaijan and BGI.”
Thalassemia, an inherited blood dysfunction, attributable to the inadequate manufacturing of hemoglobin within the pink blood cells that ship oxygen and vitamins to all components of the physique. Folks with thalassemia have a lot much less hemoglobin than regular folks and normally undergo from delicate to extreme anemia.
The Azerbaijan Thalassemia Heart is the primary main public medical establishments preventing thalassemia within the area. This Heart not solely gives service for sufferers that suffer from this illness but additionally for folks with different genetic circumstances. The nation additionally provides a basis offering medical companies to overseas residents at this Heart.
[ad_2]
Source link
